Literature DB >> 9551966

Harnessing Syk family tyrosine kinases as signaling domains for chimeric single chain of the variable domain receptors: optimal design for T cell activation.

C J Fitzer-Attas1, D G Schindler, T Waks, Z Eshhar.   

Abstract

T cells of tumor bearers often show defective TCR-mediated signaling events and, therefore, exhibit impaired immune responses. As such, patients with heavy tumor burden are often not amenable to adoptive T cell therapy. To overcome this limitation, we have developed a chimeric receptor that joins an extracellular single chain Fv (scFv) of a specific Ab for Ag recognition to an intracellular protein tyrosine kinase (PTK) for signal propagation. Stimulation through the scFv-PTK receptor should bypass defective TCR-proximal events and directly access the T cell's effector mechanisms. In this study we describe the optimization of a scFv-PTK configuration, leading to complete T cell activation. The cytosolic PTK Syk is superior to its family member, Zap-70, for intracellular signaling. As a transmembrane (TM) domain, CD4 performs better than CD8 when plastic-immobilized Ag serves as a stimulator. However, when APC are used to trigger chimeric receptors, the need for a flexible spacer between the scFv and TM domains becomes apparent. The CD8alpha-derived hinge successfully performs this task in chimeric scFv-Syk receptors regardless of its cysteine content. A cytotoxic T cell hybridoma expressing chimeric receptor genes composed of scFv-CD8(hinge)-CD8(TM)-Syk or scFv-CD8(hinge)-CD4(TM)-Syk is efficiently stimulated to produce IL-2 upon interaction with APC and specifically lyses appropriate target cells in a non-MHC-restricted manner.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9551966

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Phosphorylation of Tyr342 in the linker region of Syk is critical for Fc epsilon RI signaling in mast cells.

Authors:  Juan Zhang; Elsa Berenstein; Reuben P Siraganian
Journal:  Mol Cell Biol       Date:  2002-12       Impact factor: 4.272

2.  Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors.

Authors:  C O Yun; K F Nolan; E J Beecham; R A Reisfeld; R P Junghans
Journal:  Neoplasia       Date:  2000 Sep-Oct       Impact factor: 5.715

3.  Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.

Authors:  Michael Hudecek; Maria-Teresa Lupo-Stanghellini; Paula L Kosasih; Daniel Sommermeyer; Michael C Jensen; Christoph Rader; Stanley R Riddell
Journal:  Clin Cancer Res       Date:  2013-04-25       Impact factor: 12.531

Review 4.  The pharmacology of second-generation chimeric antigen receptors.

Authors:  Sjoukje J C van der Stegen; Mohamad Hamieh; Michel Sadelain
Journal:  Nat Rev Drug Discov       Date:  2015-07       Impact factor: 84.694

5.  The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity.

Authors:  Michael Hudecek; Daniel Sommermeyer; Paula L Kosasih; Anne Silva-Benedict; Lingfeng Liu; Christoph Rader; Michael C Jensen; Stanley R Riddell
Journal:  Cancer Immunol Res       Date:  2014-09-11       Impact factor: 11.151

Review 6.  A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains.

Authors:  Kathryn M Cappell; James N Kochenderfer
Journal:  Nat Rev Clin Oncol       Date:  2021-07-06       Impact factor: 66.675

7.  Use of recombinant lentivirus pseudotyped with vesicular stomatitis virus glycoprotein G for efficient generation of human anti-cancer chimeric T cells by transduction of human peripheral blood lymphocytes in vitro.

Authors:  Anthony Simmons; Robert P Whitehead; Andrey A Kolokoltsov; Robert A Davey
Journal:  Virol J       Date:  2006-02-28       Impact factor: 4.099

8.  Fcgamma receptor-mediated phagocytosis in macrophages lacking the Src family tyrosine kinases Hck, Fgr, and Lyn.

Authors:  C J Fitzer-Attas; M Lowry; M T Crowley; A J Finn; F Meng; A L DeFranco; C A Lowell
Journal:  J Exp Med       Date:  2000-02-21       Impact factor: 14.307

9.  Engineering Chimeric Antigen Receptors.

Authors:  S V Kulemzin; V V Kuznetsova; M Mamonkin; A V Taranin; A A Gorchakov
Journal:  Acta Naturae       Date:  2017 Jan-Mar       Impact factor: 1.845

Review 10.  T Cell Activation Machinery: Form and Function in Natural and Engineered Immune Receptors.

Authors:  Nicholas J Chandler; Melissa J Call; Matthew E Call
Journal:  Int J Mol Sci       Date:  2020-10-08       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.